PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS).
PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.


Biotechnology

Clinical Trials

Life Sciences

Therapeutics

PolTREG S.A.

Piotr Trzonkowski

Karol Ptach

Dan Shelly

This department oversees organizational governance and strategic direction.

Supervisory Board

This department focuses on the research and development of biotechnological solutions and innovations.

Biotechnology Research

This department oversees the strategic growth initiatives and operational efficiencies within the business development function.

Business Development Operations

This department oversees the planning, execution, and management of clinical trials to evaluate the safety and effectiveness of new treatments.

Clinical Research

This department oversees the planning, execution, and completion of projects to ensure they meet their objectives and timelines.

PolTREG S.A.

Org chart

Teams

Supervisory Board

Biotechnology Research

Business Development Operations

Clinical Research

Project Management

Offices